世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
小児痙縮治療市場Paediatric Spasticity Treatment Market 小児痙縮治療：市場インサイト 小児痙縮は、随意運動を制御する脳や脊髄の一部が損傷することで起こります。怪我や病気が原因で小児痙縮が起こると、神経信号が筋肉に届かなくなり、継続的に筋肉が収縮するた... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリー小児痙縮治療：市場インサイト小児痙縮は、随意運動を制御する脳や脊髄の一部が損傷することで起こります。怪我や病気が原因で小児痙縮が起こると、神経信号が筋肉に届かなくなり、継続的に筋肉が収縮するため、硬直や締め付けが起こり、動作や発話に支障をきたします。小児痙縮の治療には、患部の神経や筋肉に薬剤を注射する方法があります。理学療法では、筋力の増強、筋肉の可動性の向上、筋肉の協調性の改善、装具の使用、電気刺激などを行います。小児痙縮の治療のための内服薬は、痙縮の症状が悪化し、日常的な筋機能に影響を及ぼし始めた場合に考慮されます。CDCの自閉症・発達障害モニタリング（ADDM）ネットワークの推計によると、323人に1人の子供が脳性麻痺と同定され、CPと同定された子供のほとんど（77.4％）が痙性CPであった。 小児痙縮治療：市場動向 認知度の向上、医薬品開発のための研究開発の拡大が、近い将来の小児痙縮治療市場を牽引する。ライフスタイルの変化、新しく革新的な技術の開発、医療インフラの改善は、予測期間中に小児痙縮治療市場を活性化させると予想されます。新規治療薬の発売や、中国、ブラジルなどの新興国における一人当たり所得の増加が、小児痙縮治療市場をさらに牽引します。 小児痙縮治療の世界市場を牽引する要因は数多くありますが、小児痙縮治療市場の成長を阻害する要因としては、治療費の高騰、低開発国や発展途上国における認知度の低さ、医薬品承認のための厳格な規制などが挙げられます。 小児痙縮治療：セグメンテーション 世界の小児痙縮治療市場は、薬剤の種類、流通チャネル、地域によってセグメント化されています。 薬剤タイプ別セグメント バクロフェンまたは筋弛緩薬 ボトックス バクロフェン髄腔内投与 クロナゼパム ジアゼパム チザニジン その他 投与経路別セグメント 経口 注射剤 流通チャネル別セグメント 病院 薬局 ドラッグストア 小売薬局 通信販売薬局 小児痙縮の治療概要 新しい治療法の進歩や開発、小児痙縮治療の臨床試験の増加は、予測期間中に小児痙縮治療市場が成長するための大きな機会を生み出します。新薬開発のための大手企業間の連携やパートナーシップ、研究資金の増加は、近い将来、小児痙縮治療市場を牽引するでしょう。例えば、2016年8月、FDAはIpsenのDysport（abobotulinumtoxina）注射を2歳以上の小児の下肢痙縮の治療薬として承認した。 小児痙縮治療：地域別展望 人口の増加、スクリーニングの増加、主要メーカーの存在、臨床試験の増加により、北米が世界の小児痙縮治療において大きなシェアを占めると予想される。発達した医療施設と医薬品開発のための政府資金が、小児痙縮治療市場をさらに牽引しています。欧州は、新しい治療法の採用が増加していることと、治療における技術的進歩により、世界の小児痙縮治療市場において著しい成長を遂げ、第2位のシェアを占めています。アジア太平洋市場は、主に有病率の増加、人口の増加、新しい治療オプションに対する意識の高まりといった要因によって牽引されています。中国は、患者数が多く、小児痙縮治療のための新薬が入手可能であることから、小児痙縮治療市場において急速な成長が見込まれています。ラテンアメリカと中東・アフリカは小児痙縮治療市場の成長が鈍化すると予測されるが、これは認知度の低さ、適切な医療施設の不足、インフラの未整備が原因である。 小児痙縮治療：主要プレイヤー 世界の小児痙縮治療市場に参入している主要企業には、Allergan plc、Ipsen Biopharmaceuticals, Inc、Almirall, S.A、Piramal Critical Care, Inc、Genentech, Inc、Sanofi、Saol Therapeutics、US WorldMeds, LLCなどがあります。 本レポートでは、以下の項目について網羅的に分析しています、 小児痙縮治療市場セグメント 小児痙縮治療市場のダイナミクス 過去の市場規模（2012年〜2016年 小児痙縮治療市場規模・予測：2016年～2024年 小児痙縮治療市場の最新動向/課題/チャレンジ 競合・参入企業 小児痙縮治療市場の促進要因と阻害要因 地域別分析 北米 ラテンアメリカ ヨーロッパ アジア太平洋 中国を除く 中国 中東・アフリカ レポートのハイライト 業界ダイナミクスの変化 詳細な市場セグメンテーション 過去、現在、予測される業界規模 最新の業界動向 主な競合状況 主要企業の戦略と製品提供 成長が期待されるニッチ・セグメント／地域 市場パフォーマンスに対する中立的な視点 注 - レポートに記載されている事実、意見、分析の記述はすべて各アナリストのものです。これらは必ずしもFuture Market Insightsの正式な立場や見解を反映するものではありません。 目次1. Executive Summary1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Investment Feasibility Matrix 3.6. PESTLE and Porter’s Analysis 3.7. Regulatory Landscape 3.7.1. By Key Regions 3.7.2. By Key Countries 3.8. Regional Parent Market Outlook 4. Global Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast, 2022-2032 4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021 4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Mn) Analysis By Drug Type, 2017-2021 5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Type, 2022-2032 5.3.1. Baclofen or Muscle Relaxants 5.3.2. Botox 5.3.3. Intrathecal Baclofen 5.3.4. Clonazepam 5.3.5. Diazepam 5.3.6. Tizanidine 5.3.7. Others 5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2017-2021 5.5. Absolute $ Opportunity Analysis By Drug Type, 2022-2032 6. Global Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Mn) Analysis By Route of Administration, 2017-2021 6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Route of Administration, 2022-2032 6.3.1. Oral 6.3.2. Injectable 6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2017-2021 6.5. Absolute $ Opportunity Analysis By Route of Administration, 2022-2032 7. Global Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2017-2021 7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2032 7.3.1. Hospitals Pharmacies 7.3.2. Drug Stores 7.3.3. Retail Pharmacies 7.3.4. Mail Order Pharmacies 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017-2021 7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022-2032 8. Global Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021 8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. Asia Pacific 8.3.5. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 9.2.1. By Country 9.2.1.1. U.S. 9.2.1.2. Canada 9.2.2. By Drug Type 9.2.3. By Route of Administration 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Type 9.3.3. By Route of Administration 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug Type 10.2.3. By Route of Administration 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Type 10.3.3. By Route of Administration 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Europe Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. Italy 11.2.1.3. France 11.2.1.4. U.K. 11.2.1.5. Russia 11.2.1.6. BENELUX 11.2.1.7. Rest of Europe 11.2.2. By Drug Type 11.2.3. By Route of Administration 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Type 11.3.3. By Route of Administration 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. Asia Pacific Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.1.4. Rest of Asia Pacific 12.2.2. By Drug Type 12.2.3. By Route of Administration 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Type 12.3.3. By Route of Administration 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. Middle East and Africa Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 13.2.1. By Country 13.2.1.1. GCC Countries 13.2.1.2. South Africa 13.2.1.3. Turkey 13.2.1.4. Rest of Middle East and Africa 13.2.2. By Drug Type 13.2.3. By Route of Administration 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Type 13.3.3. By Route of Administration 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. Key Countries Paediatric Spasticity Treatment Market Analysis 14.1. U.S. 14.1.1. Pricing Analysis 14.1.2. Market Share Analysis, 2021 14.1.2.1. By Drug Type 14.1.2.2. By Route of Administration 14.1.2.3. By Distribution Channel 14.2. Canada 14.2.1. Pricing Analysis 14.2.2. Market Share Analysis, 2021 14.2.2.1. By Drug Type 14.2.2.2. By Route of Administration 14.2.2.3. By Distribution Channel 14.3. Brazil 14.3.1. Pricing Analysis 14.3.2. Market Share Analysis, 2021 14.3.2.1. By Drug Type 14.3.2.2. By Route of Administration 14.3.2.3. By Distribution Channel 14.4. Mexico 14.4.1. Pricing Analysis 14.4.2. Market Share Analysis, 2021 14.4.2.1. By Drug Type 14.4.2.2. By Route of Administration 14.4.2.3. By Distribution Channel 14.5. Germany 14.5.1. Pricing Analysis 14.5.2. Market Share Analysis, 2021 14.5.2.1. By Drug Type 14.5.2.2. By Route of Administration 14.5.2.3. By Distribution Channel 14.6. Italy 14.6.1. Pricing Analysis 14.6.2. Market Share Analysis, 2021 14.6.2.1. By Drug Type 14.6.2.2. By Route of Administration 14.6.2.3. By Distribution Channel 14.7. France 14.7.1. Pricing Analysis 14.7.2. Market Share Analysis, 2021 14.7.2.1. By Drug Type 14.7.2.2. By Route of Administration 14.7.2.3. By Distribution Channel 14.8. U.K. 14.8.1. Pricing Analysis 14.8.2. Market Share Analysis, 2021 14.8.2.1. By Drug Type 14.8.2.2. By Route of Administration 14.8.2.3. By Distribution Channel 14.9. Russia 14.9.1. Pricing Analysis 14.9.2. Market Share Analysis, 2021 14.9.2.1. By Drug Type 14.9.2.2. By Route of Administration 14.9.2.3. By Distribution Channel 14.10. BENELUX 14.10.1. Pricing Analysis 14.10.2. Market Share Analysis, 2021 14.10.2.1. By Drug Type 14.10.2.2. By Route of Administration 14.10.2.3. By Distribution Channel 14.11. China 14.11.1. Pricing Analysis 14.11.2. Market Share Analysis, 2021 14.11.2.1. By Drug Type 14.11.2.2. By Route of Administration 14.11.2.3. By Distribution Channel 14.12. Japan 14.12.1. Pricing Analysis 14.12.2. Market Share Analysis, 2021 14.12.2.1. By Drug Type 14.12.2.2. By Route of Administration 14.12.2.3. By Distribution Channel 14.13. South Korea 14.13.1. Pricing Analysis 14.13.2. Market Share Analysis, 2021 14.13.2.1. By Drug Type 14.13.2.2. By Route of Administration 14.13.2.3. By Distribution Channel 14.14. GCC Countries 14.14.1. Pricing Analysis 14.14.2. Market Share Analysis, 2021 14.14.2.1. By Drug Type 14.14.2.2. By Route of Administration 14.14.2.3. By Distribution Channel 14.15. South Africa 14.15.1. Pricing Analysis 14.15.2. Market Share Analysis, 2021 14.15.2.1. By Drug Type 14.15.2.2. By Route of Administration 14.15.2.3. By Distribution Channel 14.16. Turkey 14.16.1. Pricing Analysis 14.16.2. Market Share Analysis, 2021 14.16.2.1. By Drug Type 14.16.2.2. By Route of Administration 14.16.2.3. By Distribution Channel 15. Market Structure Analysis 15.1. Competition Dashboard 15.2. Competition Benchmarking 15.3. Market Share Analysis of Top Players 15.3.1. By Regional 15.3.2. By Drug Type 15.3.3. By Route of Administration 15.3.4. By Distribution Channel 16. Competition Analysis 16.1. Competition Deep Dive 16.1.1. Allergan plc 16.1.1.1. Overview 16.1.1.2. Product Portfolio 16.1.1.3. Profitability by Market Segments 16.1.1.4. Sales Footprint 16.1.1.5. Strategy Overview 16.1.1.5.1. Marketing Strategy 16.1.2. Ipsen Biopharmaceuticals 16.1.2.1. Overview 16.1.2.2. Product Portfolio 16.1.2.3. Profitability by Market Segments 16.1.2.4. Sales Footprint 16.1.2.5. Strategy Overview 16.1.2.5.1. Marketing Strategy 16.1.3. Almirall 16.1.3.1. Overview 16.1.3.2. Product Portfolio 16.1.3.3. Profitability by Market Segments 16.1.3.4. Sales Footprint 16.1.3.5. Strategy Overview 16.1.3.5.1. Marketing Strategy 16.1.4. Piramal Critical Care 16.1.4.1. Overview 16.1.4.2. Product Portfolio 16.1.4.3. Profitability by Market Segments 16.1.4.4. Sales Footprint 16.1.4.5. Strategy Overview 16.1.4.5.1. Marketing Strategy 16.1.5. Genentech 16.1.5.1. Overview 16.1.5.2. Product Portfolio 16.1.5.3. Profitability by Market Segments 16.1.5.4. Sales Footprint 16.1.5.5. Strategy Overview 16.1.5.5.1. Marketing Strategy 16.1.6. Sanofi 16.1.6.1. Overview 16.1.6.2. Product Portfolio 16.1.6.3. Profitability by Market Segments 16.1.6.4. Sales Footprint 16.1.6.5. Strategy Overview 16.1.6.5.1. Marketing Strategy 16.1.7. Saol Therapeutics 16.1.7.1. Overview 16.1.7.2. Product Portfolio 16.1.7.3. Profitability by Market Segments 16.1.7.4. Sales Footprint 16.1.7.5. Strategy Overview 16.1.7.5.1. Marketing Strategy 16.1.8. US WorldMeds 16.1.8.1. Overview 16.1.8.2. Product Portfolio 16.1.8.3. Profitability by Market Segments 16.1.8.4. Sales Footprint 16.1.8.5. Strategy Overview 16.1.8.5.1. Marketing Strategy 17. Assumptions & Acronyms Used 18. Research Methodology
SummaryPaediatric Spasticity Treatment: Market Insights Table of Contents1. Executive Summary1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Investment Feasibility Matrix 3.6. PESTLE and Porter’s Analysis 3.7. Regulatory Landscape 3.7.1. By Key Regions 3.7.2. By Key Countries 3.8. Regional Parent Market Outlook 4. Global Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast, 2022-2032 4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021 4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Mn) Analysis By Drug Type, 2017-2021 5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Type, 2022-2032 5.3.1. Baclofen or Muscle Relaxants 5.3.2. Botox 5.3.3. Intrathecal Baclofen 5.3.4. Clonazepam 5.3.5. Diazepam 5.3.6. Tizanidine 5.3.7. Others 5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2017-2021 5.5. Absolute $ Opportunity Analysis By Drug Type, 2022-2032 6. Global Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Mn) Analysis By Route of Administration, 2017-2021 6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Route of Administration, 2022-2032 6.3.1. Oral 6.3.2. Injectable 6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2017-2021 6.5. Absolute $ Opportunity Analysis By Route of Administration, 2022-2032 7. Global Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2017-2021 7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2032 7.3.1. Hospitals Pharmacies 7.3.2. Drug Stores 7.3.3. Retail Pharmacies 7.3.4. Mail Order Pharmacies 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017-2021 7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022-2032 8. Global Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021 8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. Asia Pacific 8.3.5. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 9.2.1. By Country 9.2.1.1. U.S. 9.2.1.2. Canada 9.2.2. By Drug Type 9.2.3. By Route of Administration 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Type 9.3.3. By Route of Administration 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug Type 10.2.3. By Route of Administration 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Type 10.3.3. By Route of Administration 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Europe Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. Italy 11.2.1.3. France 11.2.1.4. U.K. 11.2.1.5. Russia 11.2.1.6. BENELUX 11.2.1.7. Rest of Europe 11.2.2. By Drug Type 11.2.3. By Route of Administration 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Type 11.3.3. By Route of Administration 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. Asia Pacific Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.1.4. Rest of Asia Pacific 12.2.2. By Drug Type 12.2.3. By Route of Administration 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Type 12.3.3. By Route of Administration 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. Middle East and Africa Paediatric Spasticity Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 13.2.1. By Country 13.2.1.1. GCC Countries 13.2.1.2. South Africa 13.2.1.3. Turkey 13.2.1.4. Rest of Middle East and Africa 13.2.2. By Drug Type 13.2.3. By Route of Administration 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Type 13.3.3. By Route of Administration 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. Key Countries Paediatric Spasticity Treatment Market Analysis 14.1. U.S. 14.1.1. Pricing Analysis 14.1.2. Market Share Analysis, 2021 14.1.2.1. By Drug Type 14.1.2.2. By Route of Administration 14.1.2.3. By Distribution Channel 14.2. Canada 14.2.1. Pricing Analysis 14.2.2. Market Share Analysis, 2021 14.2.2.1. By Drug Type 14.2.2.2. By Route of Administration 14.2.2.3. By Distribution Channel 14.3. Brazil 14.3.1. Pricing Analysis 14.3.2. Market Share Analysis, 2021 14.3.2.1. By Drug Type 14.3.2.2. By Route of Administration 14.3.2.3. By Distribution Channel 14.4. Mexico 14.4.1. Pricing Analysis 14.4.2. Market Share Analysis, 2021 14.4.2.1. By Drug Type 14.4.2.2. By Route of Administration 14.4.2.3. By Distribution Channel 14.5. Germany 14.5.1. Pricing Analysis 14.5.2. Market Share Analysis, 2021 14.5.2.1. By Drug Type 14.5.2.2. By Route of Administration 14.5.2.3. By Distribution Channel 14.6. Italy 14.6.1. Pricing Analysis 14.6.2. Market Share Analysis, 2021 14.6.2.1. By Drug Type 14.6.2.2. By Route of Administration 14.6.2.3. By Distribution Channel 14.7. France 14.7.1. Pricing Analysis 14.7.2. Market Share Analysis, 2021 14.7.2.1. By Drug Type 14.7.2.2. By Route of Administration 14.7.2.3. By Distribution Channel 14.8. U.K. 14.8.1. Pricing Analysis 14.8.2. Market Share Analysis, 2021 14.8.2.1. By Drug Type 14.8.2.2. By Route of Administration 14.8.2.3. By Distribution Channel 14.9. Russia 14.9.1. Pricing Analysis 14.9.2. Market Share Analysis, 2021 14.9.2.1. By Drug Type 14.9.2.2. By Route of Administration 14.9.2.3. By Distribution Channel 14.10. BENELUX 14.10.1. Pricing Analysis 14.10.2. Market Share Analysis, 2021 14.10.2.1. By Drug Type 14.10.2.2. By Route of Administration 14.10.2.3. By Distribution Channel 14.11. China 14.11.1. Pricing Analysis 14.11.2. Market Share Analysis, 2021 14.11.2.1. By Drug Type 14.11.2.2. By Route of Administration 14.11.2.3. By Distribution Channel 14.12. Japan 14.12.1. Pricing Analysis 14.12.2. Market Share Analysis, 2021 14.12.2.1. By Drug Type 14.12.2.2. By Route of Administration 14.12.2.3. By Distribution Channel 14.13. South Korea 14.13.1. Pricing Analysis 14.13.2. Market Share Analysis, 2021 14.13.2.1. By Drug Type 14.13.2.2. By Route of Administration 14.13.2.3. By Distribution Channel 14.14. GCC Countries 14.14.1. Pricing Analysis 14.14.2. Market Share Analysis, 2021 14.14.2.1. By Drug Type 14.14.2.2. By Route of Administration 14.14.2.3. By Distribution Channel 14.15. South Africa 14.15.1. Pricing Analysis 14.15.2. Market Share Analysis, 2021 14.15.2.1. By Drug Type 14.15.2.2. By Route of Administration 14.15.2.3. By Distribution Channel 14.16. Turkey 14.16.1. Pricing Analysis 14.16.2. Market Share Analysis, 2021 14.16.2.1. By Drug Type 14.16.2.2. By Route of Administration 14.16.2.3. By Distribution Channel 15. Market Structure Analysis 15.1. Competition Dashboard 15.2. Competition Benchmarking 15.3. Market Share Analysis of Top Players 15.3.1. By Regional 15.3.2. By Drug Type 15.3.3. By Route of Administration 15.3.4. By Distribution Channel 16. Competition Analysis 16.1. Competition Deep Dive 16.1.1. Allergan plc 16.1.1.1. Overview 16.1.1.2. Product Portfolio 16.1.1.3. Profitability by Market Segments 16.1.1.4. Sales Footprint 16.1.1.5. Strategy Overview 16.1.1.5.1. Marketing Strategy 16.1.2. Ipsen Biopharmaceuticals 16.1.2.1. Overview 16.1.2.2. Product Portfolio 16.1.2.3. Profitability by Market Segments 16.1.2.4. Sales Footprint 16.1.2.5. Strategy Overview 16.1.2.5.1. Marketing Strategy 16.1.3. Almirall 16.1.3.1. Overview 16.1.3.2. Product Portfolio 16.1.3.3. Profitability by Market Segments 16.1.3.4. Sales Footprint 16.1.3.5. Strategy Overview 16.1.3.5.1. Marketing Strategy 16.1.4. Piramal Critical Care 16.1.4.1. Overview 16.1.4.2. Product Portfolio 16.1.4.3. Profitability by Market Segments 16.1.4.4. Sales Footprint 16.1.4.5. Strategy Overview 16.1.4.5.1. Marketing Strategy 16.1.5. Genentech 16.1.5.1. Overview 16.1.5.2. Product Portfolio 16.1.5.3. Profitability by Market Segments 16.1.5.4. Sales Footprint 16.1.5.5. Strategy Overview 16.1.5.5.1. Marketing Strategy 16.1.6. Sanofi 16.1.6.1. Overview 16.1.6.2. Product Portfolio 16.1.6.3. Profitability by Market Segments 16.1.6.4. Sales Footprint 16.1.6.5. Strategy Overview 16.1.6.5.1. Marketing Strategy 16.1.7. Saol Therapeutics 16.1.7.1. Overview 16.1.7.2. Product Portfolio 16.1.7.3. Profitability by Market Segments 16.1.7.4. Sales Footprint 16.1.7.5. Strategy Overview 16.1.7.5.1. Marketing Strategy 16.1.8. US WorldMeds 16.1.8.1. Overview 16.1.8.2. Product Portfolio 16.1.8.3. Profitability by Market Segments 16.1.8.4. Sales Footprint 16.1.8.5. Strategy Overview 16.1.8.5.1. Marketing Strategy 17. Assumptions & Acronyms Used 18. Research Methodology
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療）の最新刊レポート
Future Market Insights社の医療・製薬・メディカルデバイス分野での最新刊レポート本レポートと同じKEY WORD（）の最新刊レポート
よくあるご質問Future Market Insights社はどのような調査会社ですか?Future Market Insights（FMI）は世界の広範な地域および産業を対象にした調査レポートを出版しています。 弊社ウェブサイトに掲載のないタイトルも全てお取り扱い可能ですので... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|